在男性,非糖尿病老年人中,使用他类药物和腹腔大动脉结之间的关联
Meng Wang1, Changju Liu1, Hongjian Shan2
1Department of Endocrinology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Current vascular pharmacology
|March 4, 2025
概括
立方体使用与腹部大动脉化 (AAC) 患病率增加有关,特别是严重的AAC. 这种关联在男性,非糖尿病患者和60岁以上的个人中更为明显.
科学领域:
- 心血管健康 心血管健康
- 药理学 药理学是指药理学的学科.
- 医疗成像医学成像
背景情况:
- 腹腔大动脉化 (AAC) 是心血管风险的标志物.
- 类他类药物是广泛处方的降脂药物.
- 对于他类药物使用与AAC患病率之间的关系,需要进一步调查.
研究的目的:
- 检查他类药物使用与腹腔大动脉化 (AAC) 的患病率之间的关联.
- 评估与任何AAC和严重AAC的关联.
- 为了探索这个协会中的子组差异.
主要方法:
- 利用了2013-2014年国家健康和营养检查调查 (NHANES) 的数据.
- 通过自我报告的药物历史来评估他类药物的使用.
- 使用双能X射线吸收度 (DXA) 和后勤回归分析量化AAC和严重AAC.
主要成果:
- 该研究包括2074名参与者 (44.5%是男性,平均年龄为61.6岁).
- 在35.4%的参与者中存在AAC,在12.0%的参与者中存在严重的AAC.
- 调整后的分析显示,他类药物的使用与AAC (OR 1.28) 和严重AAC (OR 1.78) 的更高几率有关.
- 在男性,非糖尿病患者和60岁以上的人群中,相关性更强.
结论:
- 立方体使用与腹腔大动脉化 (AAC) 和严重的AAC的更大患病率有关.
- 这种关联在特定的子组中更为显著:男性,非糖尿病患者和60岁以上的人.
- 进一步的研究可能会阐明这种观察到的关联背后的机制.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


